| Literature DB >> 26419959 |
Kosuke Mima1, Reiko Nishihara2, Jonathan A Nowak3, Sun A Kim1, Mingyang Song4, Kentaro Inamura1, Yasutaka Sukawa1, Atsuhiro Masuda1, Juhong Yang1, Ruoxu Dou1, Katsuhiko Nosho5, Hideo Baba6, Edward L Giovannucci7, Michaela Bowden1, Massimo Loda8, Marios Giannakis9, Adam J Bass10, Glenn Dranoff11, Gordon J Freeman1, Andrew T Chan12, Charles S Fuchs13, Zhi Rong Qian14, Shuji Ogino15.
Abstract
The complex interactions between colorectal neoplasia and immune cells in the tumor microenvironment remain to be elucidated. Experimental evidence suggests that microRNA MIR21 (miR-21) suppresses antitumor T-cell-mediated immunity. Thus, we hypothesized that tumor MIR21 expression might be inversely associated with T-cell density in colorectal carcinoma tissue. Using 538 rectal and colon cancer cases from the Nurses' Health Study and the Health Professionals Follow-up Study, we measured tumor MIR21 expression by a quantitative reverse-transcription PCR assay. Densities of CD3(+), CD8(+), CD45RO (PTPRC)(+), and FOXP3(+) cells in tumor tissue were determined by tissue microarray immunohistochemistry and computer-assisted image analysis. Ordinal logistic regression analysis was conducted to assess the association of MIR21 expression (ordinal quartiles as a predictor variable) with T-cell density (ordinal quartiles as an outcome variable), adjusting for tumor molecular features, including microsatellite instability; CpG island methylator phenotype; KRAS, BRAF, and PIK3CA mutations; and LINE-1 methylation. We adjusted the two-sided α level to 0.012 for multiple hypothesis testing. Tumor MIR21 expression was inversely associated with densities of CD3(+) and CD45RO(+) cells (Ptrend < 0.0005). The multivariate odds ratio of the highest versus lowest quartile of MIR21 for a unit increase in quartile categories of CD3(+) or CD45RO(+) cells was 0.44 [95% confidence interval (CI), 0.28 to 0.68] or 0.41 (95% CI, 0.26-0.64), respectively. Our data support a possible role of tumor epigenetic deregulation by noncoding RNA in suppressing the antitumor T-cell-mediated adaptive immune response and suggest MIR21 as a potential target for immunotherapy and prevention in colorectal cancer. ©2015 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26419959 PMCID: PMC4703429 DOI: 10.1158/2326-6066.CIR-15-0084
Source DB: PubMed Journal: Cancer Immunol Res ISSN: 2326-6066 Impact factor: 11.151